Fostamatinib Disodium | ||||
CAS NO.: | 1025687-58-4 | |||
Chemical Formula: | C23H24FN6Na2O9P | |||
Molecular Weight: | 624.4000 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Fostamatinib Disodium Anhydrous is the anhydrous form of fostamatinib disodium, an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.
**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
FOSTAMATINIB DISODIUM | TABLET;ORAL | EQ 100MG BASE | TAVALISSE | RIGEL PHARMACEUTICALS INC |
FOSTAMATINIB DISODIUM | TABLET;ORAL | EQ 150MG BASE | TAVALISSE | RIGEL PHARMACEUTICALS INC |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
N.A. | N.A. | N.A. | N.A. | N.A. |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
NCE | 04/17/2023 | |||
ODE-174 | 04/17/2025 | |||